FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202364162> ?p ?o ?g. }

• W3202364162 endingPage "26" @default.
• W3202364162 startingPage "18" @default.
• W3202364162 abstract "Objectives To investigate the recent real‐world use of first‐generation antiandrogens (FGAs) in metastatic castration‐resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients and Methods The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan–Meier method and groups compared using log‐rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model. Results We identified 634 patients with mCRPC, enrolled in ePAD between January 2016 and March 2019, including 322 (51%) who received FGAs. The median follow‐up was 21.9 months. Patients treated with FGAs were more likely to have lower International Society of Urological Pathologists (ISUP) grade group ( P = 0.04), longer median time to CRPC (25.6 vs 16.0 months, P < 0.001), and were less likely to have visceral metastases (5.0% vs 11.2%, P = 0.005) or to have received upfront docetaxel ( P < 0.001). A ≥50% reduction from pre‐treatment prostate‐specific antigen (PSA) level (PSA50 response) during FGA treatment occurred in 119 (37%) patients and was independently associated with improved OS (hazard ratio 0.233, P < 0.001). Prior FGA treatment did not significantly influence the selection of subsequent life‐prolonging treatments for mCRPC or their PSA50 response rates. Conclusion In our present cohort, FGAs were commonly used in lower‐risk mCRPC and their use did not significantly influence the choice or duration of subsequent systemic therapy. A PSA50 response to FGA therapy was an independent favourable prognostic marker associated with improved OS." @default.
• W3202364162 created "2021-10-11" @default.
• W3202364162 creator A5000291176 @default.
• W3202364162 creator A5003414034 @default.
• W3202364162 creator A5006719945 @default.
• W3202364162 creator A5010549911 @default.
• W3202364162 creator A5011946923 @default.
• W3202364162 creator A5018801649 @default.
• W3202364162 creator A5040246688 @default.
• W3202364162 creator A5044715236 @default.
• W3202364162 creator A5055735681 @default.
• W3202364162 creator A5057831510 @default.
• W3202364162 creator A5067802897 @default.
• W3202364162 creator A5075093609 @default.
• W3202364162 creator A5082697210 @default.
• W3202364162 creator A5085199410 @default.
• W3202364162 creator A5085333470 @default.
• W3202364162 creator A5086080884 @default.
• W3202364162 creator A5089420153 @default.
• W3202364162 creator A5090641762 @default.
• W3202364162 date "2021-10-01" @default.
• W3202364162 modified "2023-09-24" @default.
• W3202364162 title "Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer" @default.
• W3202364162 cites W2014476883 @default.
• W3202364162 cites W2026851921 @default.
• W3202364162 cites W2071503820 @default.
• W3202364162 cites W2150865892 @default.
• W3202364162 cites W2214621962 @default.
• W3202364162 cites W2239698670 @default.
• W3202364162 cites W2252849995 @default.
• W3202364162 cites W2278392405 @default.
• W3202364162 cites W2464502417 @default.
• W3202364162 cites W2489425084 @default.
• W3202364162 cites W2494606416 @default.
• W3202364162 cites W2511755939 @default.
• W3202364162 cites W2565926341 @default.
• W3202364162 cites W2620746860 @default.
• W3202364162 cites W2620798309 @default.
• W3202364162 cites W2770618512 @default.
• W3202364162 cites W2787804990 @default.
• W3202364162 cites W2893032773 @default.
• W3202364162 cites W2898907911 @default.
• W3202364162 cites W2900079814 @default.
• W3202364162 cites W2911188335 @default.
• W3202364162 cites W2912370825 @default.
• W3202364162 cites W2918138110 @default.
• W3202364162 cites W2934898666 @default.
• W3202364162 cites W2945185023 @default.
• W3202364162 cites W2947893479 @default.
• W3202364162 cites W2972533565 @default.
• W3202364162 cites W2975895768 @default.
• W3202364162 cites W2981468397 @default.
• W3202364162 cites W3033528116 @default.
• W3202364162 doi "https://doi.org/10.1111/bju.15364" @default.
• W3202364162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34622543" @default.
• W3202364162 hasPublicationYear "2021" @default.
• W3202364162 type Work @default.
• W3202364162 sameAs 3202364162 @default.
• W3202364162 citedByCount "0" @default.
• W3202364162 crossrefType "journal-article" @default.
• W3202364162 hasAuthorship W3202364162A5000291176 @default.
• W3202364162 hasAuthorship W3202364162A5003414034 @default.
• W3202364162 hasAuthorship W3202364162A5006719945 @default.
• W3202364162 hasAuthorship W3202364162A5010549911 @default.
• W3202364162 hasAuthorship W3202364162A5011946923 @default.
• W3202364162 hasAuthorship W3202364162A5018801649 @default.
• W3202364162 hasAuthorship W3202364162A5040246688 @default.
• W3202364162 hasAuthorship W3202364162A5044715236 @default.
• W3202364162 hasAuthorship W3202364162A5055735681 @default.
• W3202364162 hasAuthorship W3202364162A5057831510 @default.
• W3202364162 hasAuthorship W3202364162A5067802897 @default.
• W3202364162 hasAuthorship W3202364162A5075093609 @default.
• W3202364162 hasAuthorship W3202364162A5082697210 @default.
• W3202364162 hasAuthorship W3202364162A5085199410 @default.
• W3202364162 hasAuthorship W3202364162A5085333470 @default.
• W3202364162 hasAuthorship W3202364162A5086080884 @default.
• W3202364162 hasAuthorship W3202364162A5089420153 @default.
• W3202364162 hasAuthorship W3202364162A5090641762 @default.
• W3202364162 hasBestOaLocation W32023641621 @default.
• W3202364162 hasConcept C121608353 @default.
• W3202364162 hasConcept C126322002 @default.
• W3202364162 hasConcept C126894567 @default.
• W3202364162 hasConcept C143998085 @default.
• W3202364162 hasConcept C167135981 @default.
• W3202364162 hasConcept C207103383 @default.
• W3202364162 hasConcept C2779322244 @default.
• W3202364162 hasConcept C2780192828 @default.
• W3202364162 hasConcept C2781190966 @default.
• W3202364162 hasConcept C2781406297 @default.
• W3202364162 hasConcept C2910016293 @default.
• W3202364162 hasConcept C29456083 @default.
• W3202364162 hasConcept C44249647 @default.
• W3202364162 hasConcept C50382708 @default.
• W3202364162 hasConcept C71924100 @default.
• W3202364162 hasConcept C72563966 @default.
• W3202364162 hasConceptScore W3202364162C121608353 @default.
• W3202364162 hasConceptScore W3202364162C126322002 @default.
• W3202364162 hasConceptScore W3202364162C126894567 @default.

• next